Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
Pending LLM rewrite. Source: FDA_DRUG D-0316-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0312-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0336-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0324-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0325-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0321-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0326-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0310-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0337-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0361-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0360-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0320-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0314-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0341-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0330-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0333-2025.
Glenmark Pharmaceuticals is voluntarily recalling Cetirizine HCL 10mg tablets distributed nationwide. The recall was initiated due to Current Good Manufacturing Practice deviations.
Glenmark Pharmaceuticals is voluntarily recalling Voriconazole tablets nationwide due to manufacturing process deviations. No illnesses or injuries have been reported.
Asegua Therapeutics is recalling 18,541 cartons of Sofosbuvir and Velpatasvir tablets nationwide due to defective blister packs that are not properly sealed, resulting in loose tablets in cartons. No illnesses or injuries have been reported.
Glenmark Pharmaceuticals is recalling solifenacin succinate 10mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects specific lot numbers distributed across the United States.
Glenmark Pharmaceuticals is recalling Saxagliptin 2.5mg tablets nationwide due to manufacturing quality issues. The firm initiated this voluntary recall on March 13, 2025.
Glenmark Pharmaceuticals is recalling Rufinamide 200mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects certain lot numbers with July 2025 expiration dates.
Glenmark Pharmaceuticals is voluntarily recalling Pravastatin Sodium 80mg tablets due to Current Good Manufacturing Practice deviations. The nationwide recall affects specific lot numbers and remains ongoing.
Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.
Glenmark Pharmaceuticals is voluntarily recalling Indomethacin Extended-Release Capsules (75mg) distributed nationwide due to Good Manufacturing Practice deviations identified during FDA oversight.